Uses
MA-0204 is a potent, highly selective and orally available peroxisome proliferator activated receptor δ (PPARδ) modulator with EC50s of 0.4 nM, 7.9 nM and 10 nM for human, mouse and rat PPARδ, respectively. Potential treatment for Duchene Muscular Dystrophy (DMD)[1].
in vivo
PPARδ (30, 100 mg/kg) increases target gene transcription in the muscle[1].
IC 50
PPARδ: 0.4 nM (EC
50, in human); PPARδ: 7.9 nM (EC
50, in mouse); PPARδ: 10 nM (EC
50, in rat)
References
[1] Lagu B, et al. Selective PPARδ Modulators Improve Mitochondrial Function: Potential Treatment for Duchenne Muscular Dystrophy (DMD). ACS Med Chem Lett. 2018 Jul 31;9(9):935-940. DOI:
10.1021/acsmedchemlett.8b00287
